Moving beyond simple technologies that merely incorporated drugs into erodible or inert polymers as release platforms, 80 papers review recent developments in design and manufacturing techniques related to modified-release drug delivery systems. With the exception of a final section addressing regul
Modified-Release Drug Delivery Technology (Drugs and the Pharmaceutical Sciences)
โ Scribed by Michael J. Rathbone, Jonathan Hadgraft, Michael S. Roberts
- Publisher
- Informa Healthcare
- Year
- 2002
- Tongue
- English
- Leaves
- 962
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
Describing formulation challenges and their solutions in the design, development, and commercialization of modified-release drugs delivery systems, this book contains eighty papers that review recent developments in design and manufacturing techniques. It includes detailed descriptions of extended release drug products for the oral, nasal, ophthalmic, pulmonary, vaginal, dermal and transdermal pathways. With the exception of the final section addressing regulatory issues, each section covers a particular route for drug delivery and opens with an overview of the anatomical, physiological, and pharmaceutical basics of each route before moving on to cover specific technologies.
โฆ Table of Contents
I. INTRODUCTION......Page 1
REFERENCES......Page 7
A. Demonstration of Safety and Ef.cacy Primarily Based on Clinical Trials......Page 4
REFERENCES......Page 15
REFERENCES......Page 22
III. CONTROLLED-RELEASE NEW DRUG APPLICATIONS......Page 2
VII. GENERIC EQUIVALENCE OF AN APPROVED CONTROLLED-RELEASE PRODUCT......Page 8
REFERENCES......Page 32
IV. CODE OF FEDERAL REGULATIONS: BIOAVAILABILITY STUDY REQUIREMENTS FOR CONTROLLED-RELEASE PRODUCTS......Page 3
IV. CLINICAL REQUIREMENTS......Page 5
B. Demonstration of Safety and Ef.cacy Based on PK, PK/PD Trials......Page 6
Table of Contents......Page 41
REFERENCES......Page 12
REFERENCES......Page 13
Table of Contents......Page 54
VII. CONCLUSION......Page 11
REFERENCES......Page 14
Table of Contents......Page 68
Table of Contents......Page 77
B. Bioequivalence Requirements......Page 9
B. Release Pro.le and Bioavailability......Page 17
Table of Contents......Page 95
VIII. SCALE-UP AND POSTAPPROVAL CHANGES FOR MODIFIED-RELEASE FORMULATIONS......Page 10
Table of Contents......Page 106
Table of Contents......Page 117
Table of Contents......Page 131
Table of Contents......Page 140
Table of Contents......Page 150
Table of Contents......Page 165
VI. COMPETITIVE ADVANTAGE AND FUTURE DIRECTIONS......Page 21
Table of Contents......Page 190
Table of Contents......Page 204
Table of Contents......Page 215
Table of Contents......Page 229
Table of Contents......Page 235
Table of Contents......Page 245
Table of Contents......Page 255
Table of Contents......Page 261
Table of Contents......Page 269
Table of Contents......Page 275
Table of Contents......Page 284
Table of Contents......Page 300
REFERENCES......Page 16
Table of Contents......Page 325
Table of Contents......Page 339
Table of Contents......Page 350
Table of Contents......Page 357
Table of Contents......Page 373
Table of Contents......Page 389
Table of Contents......Page 398
Table of Contents......Page 408
Table of Contents......Page 426
Table of Contents......Page 437
Table of Contents......Page 453
Table of Contents......Page 459
Table of Contents......Page 468
Table of Contents......Page 475
Table of Contents......Page 485
Table of Contents......Page 503
Table of Contents......Page 516
Table of Contents......Page 526
Table of Contents......Page 535
Table of Contents......Page 549
Table of Contents......Page 562
Table of Contents......Page 571
Table of Contents......Page 588
Table of Contents......Page 598
Table of Contents......Page 606
Table of Contents......Page 617
Table of Contents......Page 630
Table of Contents......Page 636
Table of Contents......Page 644
Table of Contents......Page 653
Table of Contents......Page 666
Table of Contents......Page 673
Table of Contents......Page 682
Table of Contents......Page 698
Table of Contents......Page 706
Table of Contents......Page 719
Table of Contents......Page 741
Table of Contents......Page 751
Table of Contents......Page 767
Table of Contents......Page 783
Table of Contents......Page 793
Table of Contents......Page 799
Table of Contents......Page 808
Table of Contents......Page 815
Table of Contents......Page 825
Table of Contents......Page 839
Table of Contents......Page 847
Table of Contents......Page 857
Table of Contents......Page 868
Table of Contents......Page 880
Table of Contents......Page 892
Table of Contents......Page 902
Table of Contents......Page 914
Table of Contents......Page 923
Table of Contents......Page 930
A. IVIVC......Page 23
B. Setting Dissolution Speci.cations......Page 28
X. CONCLUSION......Page 31
๐ SIMILAR VOLUMES
InterAG, Hamilton, New Zealand. Reference describes the formulation challenges and solutions encountered in the design, development, and commercialization of modified-release drug products for the oral, nasal, ophthalmic, pulmonary, vaginal, dermal, and transdermal pathways.
For over 50 years, interest has been expressed in optimizing drug therapy through delivery system design. For many years this revolved around incorporating drugs into erodible or inert polymers, which then acted as platforms for controlled release, an approach that has been well reviewed in the lite
<p>This two volume Second Edition describes the anatomical, physiological, pharmaceutical, and technological aspects of delivery routes, found in areas like:OralOcularDermal and transdermalVaginalColonicOral mucosalNasalPulmonaryProviding insight and critical assessment of the many available and eme
<P>This two volume <STRONG><EM>Second Edition</EM></STRONG> describes the anatomical, physiological, pharmaceutical, and technological aspects of delivery routes, found in areas like:</P> <P></P> <UL> <UL> <P></P></UL> <LI>Oral</LI> <LI>Ocular</LI> <LI>Dermal and transdermal</LI> <LI>Vaginal</LI> <L
Nanoparticles, products of nanotechnology, are of increasing interest to the pharmaceutical community. They can increase drug solubility, enhance bioavailability, allow tissue targeting, offer decreased side-effects, and improve therapeutic efficacy. Presenting the most pertinent and practical iss